Inhibitors of protease-activated receptor 4 (PAR4): a review of recent patents (2013-2021) [0.03%]
蛋白酶激活受体4(PAR4)抑制剂：2013—2021年近期专利综述
Xiangying Yu,Shanshan Li,Xiong Zhu et al.
Xiangying Yu et al.
Introduction: Protease-activated receptor 4 (PAR4), belonging to a subfamily of G-protein-coupled receptors (GPCR), is expressed on the surface of Human platelets, and the activation of it can lead to platelets aggregatio...
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review [0.03%]
氟-18放射示踪剂的合成方法及其在PET显像中的应用：专利综述
Sridhar Goud Nerella,Ahana Bhattacharya,Pavitra S Thacker et al.
Sridhar Goud Nerella et al.
Introduction: Fluorine-18 is a promising radionuclide for developing novel PET radiotracers due to its characteristic features such as convenient half-life, metabolic stability, good imaging properties, and easy access to...
Inhibitors of the GTPase KRASG12C in cancer: a patent review (2019-2021) [0.03%]
KRASG12C 抑制剂在癌症治疗中的应用：2019—2021年专利回顾
Qifu Xu,Guozhen Zhang,Qian Liu et al.
Qifu Xu et al.
Introduction: KRAS is one of the most important oncology proteins, which can activate multiple downstream signaling pathways. Despite the prevalence of KRAS mutations in approximately 30% of human cancers, it has long bee...
PDE1 inhibitors: a review of the recent patent literature (2008-present) [0.03%]
PDE1抑制剂专利近十年回顾（2008-今）
Mei-Ling Le,Mei-Yan Jiang,Chuan Han et al.
Mei-Ling Le et al.
Introduction: PDE1 has been demonstrated to be a potential drug target for a variety of diseases, such as Alzheimer's disease and cardiovascular disease. In the past decades, numerous PDE1 inhibitors with structural diver...
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents [0.03%]
靶向葡萄糖代谢研发抗癌药物和疗法专利
Yan Zhou,Yizhen Guo,Kin Yip Tam
Yan Zhou
Introduction: One of the most distinctive hallmarks of cancer cells is increased glucose consumption for aerobic glycolysis, which is called the Warburg effect. In recent decades, extensive research has been carried out t...
Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021) [0.03%]
选择性TYK2抑制剂作为潜在的治疗药物：2019-2021年专利回顾
Felix Gonzalez Lopez de Turiso,Kevin Guckian
Felix Gonzalez Lopez de Turiso
Introduction: Tyrosine kinase 2 (TYK2) is a member of the JAK family class of kinases that is responsible for mediating the immune response to IL-12, IL-23, and IFNα. The therapeutic value of targeting this pathway in au...
Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present [0.03%]
2014年至今癌症治疗小分子ATR抑制剂专利研究综述
Suwen Hu,Zi Hui,Jilong Duan et al.
Suwen Hu et al.
Introduction: Ataxia telangiectasia and RAD3-related kinase (ATR) is one of the key phosphatidylinositol 3-kinase-related kinase family members important for DNA damage response and repair pathways. Targeting ATR kinase f...
Daniel K Afosah,Edward Ofori,Madhusoodanan Mottamal et al.
Daniel K Afosah et al.
Introduction: Anticoagulation with no bleeding complications is the current objective of drug discovery programs in the area of treating and/or preventing thromboembolism. Despite the promises of therapeutics targeting fa...
Phosphodiesterase‑4 inhibitors: a review of current developments (2013-2021) [0.03%]
磷酸二酯酶-4抑制剂的研究进展(2013-2021)
Zhihao Liu,Mingjian Liu,Zhenqing Cao et al.
Zhihao Liu et al.
Introduction: Cyclic nucleotide phosphodiesterase 4 (PDE4) is responsible for the hydrolysis of cAMP, which has become an attractive therapeutic target for lung, skin, and severe neurological diseases. Here, we review the...
Current trends of benzothiazoles in drug discovery: a patent review (2015-2020) [0.03%]
苯并噻唑类药物发现的最新趋势：2015-2020年专利回顾
Christine Shing Wei Law,Keng Yoon Yeong
Christine Shing Wei Law
Introduction: Benzothiazole is a bicyclic ring system composed of thiazole and benzene rings. It is present as an important pharmacophore in many marketed drugs. The notable potential of benzothiazoles as therapeutic agen...